Direct Evidence of Insulin Toxicity
Majid Ali, M.D.
Here is a thought experiment. Suppose we conduct two large trials to investigate the incidence of death caused by insulin used to treat diabetes. For the first randomized trial, we take 5,000 patients with a median A1c level of 8.1% and assign them to receive intensive therapy for a target A1c value below 6.0%.. Next, we take another 5,000 patients and give them standard therapy with a target A1c level from 7.0 to 7.9%.
Needless to point out, the first group will receive more Diabetes drugs to lower A1c level with higher insulin activity, since all diabetes drugs increase insulin activity. Question: Which group will have a higher death rate, the more drugs/more insulin group or the less drugs/less insulin group?
For the second randomized trial, we take 6,000 patients admitted to ICUs in various countries. We treat 3,000 of these patients with insulin by intravenous infusions to lower the blood glucose level and reach a target of 81 to 108 mg /dL. We treat the remaining 3,000 patients without insulin drips and allow the blood glucose level to reach 180 mg/dL.
Question: Which group will have a higher death rate, the group with intravenous insulin infusion or the group without it?
If insulin in excess is toxic—I strongly assert it is—then there will be more deaths in patients given larger doses of insulin in both trials. That indeed is the case. Both insulin trials of my thought experiment have been done and published in The New England Journal of Medicine. The first was called the ACCORD trial and included 10,251 patients. The second, called the NICE-SUGAR Study, included 6,104 patients. Both trials proved that higher insulin activity was associated with higher death rates.
Below are the conclusions (verbatum) of the two trials that speak for themselves:
As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce major cardiovascular events. These findings identify a previously unrecognized harm of intensive glucose lowering in high-risk patients with type 2 diabetes (N Eng J Med. 2008;358:2560-2572. June 12, 2008 ).
It is hard to teach old dogs new tricks. So, I was not surprised to find the following words in an editorial on the subject in The New England Journal of Medicine (360:1346-1349 March 26, 2009):
Clinicians, particularly those involved in critical care, are now left in something of a quandary. Until further evidence becomes available, it would seem reasonable to continue our attempts to optimize the management of blood glucose in our hospitalized patients.
The Journal has never shown interest in the problem of grease buildup on cell membranes caused by unhealthy foods, polluted environment, and chronic anger. None of the writers of the Journal seem to understand that grease on cell membrane—composed of rancid fats, sticky sugars, pulped proteins, metabolic waste, and debris—immobilizes and incapacitates insulin receptors. They are unable to learn that insulin receptor activity can be restored by grease-removing oxygen therapies. This is how the need for insulin can be reduced—even eliminated on many occasions—for superior clinical results. This is where the real potential of de-diabetization and better care of people with diabetes can be found. Of course, there are no drugs that remove cellular grease, hence theJournal’s disdain for nondrug oxystatic therapies.
Generations of physicians believe that all nondrug, nonscalpel therapies are unscientific; and
Ethics in medicine—truth and integrity in the work of practitioners—has been endemically and perniciously compromised by the “Medical-Industrial Complex (the “Complex”), which, in 2008, controlled the $2.4 trillion disease- maintenance system in the U.S. By 2013, the number had risen to $3.2 trillion. There is no end in sight for the deepening health care crisis with the prevailing medical model—Americans continue to become sicker as enormous sums are stolen from them by the Complex. Read the entire Mission Statement